Research chemical is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-09-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
Cardarine is prohibited in competitive sport under the World Anti-Doping Agency code, where it is classified as a metabolic modulator. It is not approved as a prescription medicine in the United States, European Union, or other major markets. Regulatory action has focused on its presence in sports and in products marketed as research chemicals. Because it has no accepted medical indication, supply is often unregulated. This status creates legal and safety uncertainties for anyone who encounters the substance.
Anti-doping laboratories detect GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be used in some programs. Detection depends on factors such as dose, timing, metabolism, and the sensitivity of the assay. Published methods describe limits of detection in the low nanogram per milliliter range for related compounds. Exact detection windows are not fixed for all situations and remain an area of ongoing study.
Activation of PPARδ changes transcription of genes involved in fatty acid transport, mitochondrial function, and skeletal muscle fuel preference. In rodent studies, pharmacological PPARδ activation was associated with increased endurance and altered body composition. These findings generated interest in performance enhancement, but species differences and study designs limit direct extrapolation to humans. Small human trials were conducted in the 2000s and later discontinued. The extent to which cardarine produces similar metabolic or performance effects in people remains an open question.
The compound is typically described as a laboratory compound rather than a therapeutic product. Published reports have explored its role in lipid disorders, insulin sensitivity, and exercise metabolism, yet no major drug regulator has approved it for medical use. Commercial samples sold under the cardarine name may vary in purity and identity. Analytical confirmation is therefore necessary when the material is discussed in scientific or regulatory contexts. Its classification as a prohibited substance in sport further shapes how it is studied and reported.
Cardarine is a common name for GW501516, a synthetic compound studied for its effects on lipid and glucose metabolism. It functions as an agonist at peroxisome proliferator-activated receptor delta, or PPARδ, a nuclear receptor that influences gene expression. The molecule is not a steroid, nor is it a selective androgen receptor modulator. It is also known in research and sports literature as GW-501516 and endurobol. Early laboratory work examined its metabolic activity in cell cultures and animal models.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a metabolic modulator. |
| Approved medical use | None in major jurisdictions | Not a registered drug. |
| Common test matrix | Urine | Most anti-doping samples use urine. |
| Typical detection method | LC-MS/MS | Detects parent compound and metabolites. |
| Reference standard storage | -20 °C, desiccated | Typical for analytical standards. |
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
== Organizations == Gas Safe Register, in the United Kingdom Global Sea Mineral Resources, an underwater mining company Groupe Scolaire La Résidence, a French international school in Casablanca, Morocco
== Awards and honours == Robinson has received many honors working as a cellular biologist. She was awarded a Wellcome Trust Principal Research Fellowship in 1999 and in 2003 she was appointed Professor of Molecular Cell Biology. She was elected a Fellow of the Academy of Medical Sciences in 2001 and member of the European Molecular Biology Organization in the same year. She was elected a Fellow of the Royal Society (FRS) in 2012. The Wellcome Trust also has funded her research for over 25 years.
However, plant oils have a major limitation in availability of oil-seed supplies at competitive prices, leading to an interest in direct synthesis of fatty acid methyl esters in bacteria. This process bypasses transesterification, leading to higher energy yields and lower production cost. One of the principal obstacles in production of viable biofuels is that the maximum blend ratio of biofuel to petroleum is between 10% and 20%, Current biofuels are not compatible with high-performance, low-emission engines and costly changes in infrastructure and engine remodeling would be required. A University of Exeter study sought to overcome this obstacle through production of biofuels that can replace current fossil fuels through sustainable means, namely, the production of n-alkanes, iso-alkanes, and n-alkenes, as these are the hydrocarbons that compose current retail transport fuels. The study found suitable substrates for production of the aforementioned hydrocarbons by means of the P. luminescens fatty acid reductase (FAR) complex. A study published in Biotechnology for Biofuels used S. cerevisiae to produce short- and branched-chain alkyl esters biodiesel through metabolic engineering. Negative regulators for the INO1 gene, Rpd3 and Opi1 were deleted to boost S. cerevisiae's ability to produce fatty acid esters. To increase the production of alcohol precursors, five isobutanol pathway enzymes were overexpressed.
Arsène Wenger management career statistics at Soccerbase Arsène Wenger manager profile at J.League (archive) (in Japanese) Arsène Wenger profile at Arsenal.com Arsène Wenger at Soccerway.com Arsène Wenger at WorldFootball.net Arsène Wenger at Soccerbase.com (manager) Arsène Wenger at J.League (manager) (in Japanese) Arsène Wenger at L'Équipe (in French)
Sources: en.wikipedia.org
=== Biosynthetic corneas === On 25 August 2010, investigators from Canada and Sweden reported results from the first 10 people in the world treated with the biosynthetic corneas. Two years after having the corneas implanted, six of the 10 patients had improved vision. Nine of the 10 experienced cell and nerve regeneration, meaning that corneal cells and nerves grew into the implant. To make the material, the researchers placed a human gene that regulates the natural production of collagen into specially programmed yeast cells. They then molded the resulting material into the shape of a cornea. This research shows the potential for these bioengineered corneas but the outcomes in this study were not nearly as good as those achieved with human donor corneas. This may become an excellent technique, but right now it is still in the prototype stage and not ready for clinical use. The results were published in the journal Science Translational Medicine.
Tuberous breasts (or tubular breasts) are a result of a congenital abnormality of the breasts which can occur in both men and women (also see Hypoplasia), one breast or both. During puberty breast development is stymied and the breasts fail to develop normally and fully. The exact cause of this is as yet unclear; however, a study in 2011 of the cells in the breasts of both males and females with tubular breasts suggested a genetic link in a disorder of collagen deposition. The condition is thought to affect one to five percent of breast augmentation patients; however, the proportion of the general population affected is unknown as surgery is not always sought.
ASQ provides its members with certification, training, publications, conferences, and other services. ASQ is a founding partner of the American Customer Satisfaction Index (ACSI), a quarterly economic indicator. Since 1989, ASQ has administered the annual Malcolm Baldrige National Quality Award. The ASQ also gives the Dorian Shainin Medal, which is awarded annually for the "Development and Application of Creative or Unique Statistical Approaches in the Solving of Problems Relative to the Quality of Product or Service".
This inherited condition can be diagnosed with a blood test. If the total cholinesterase activity in the patient's blood is low, this may suggest an atypical form of the enzyme is present, putting the patient at risk of sensitivity to suxamethonium and related drugs. Inhibition studies may also be performed to give more information about potential risk. In some cases, genetic studies may be carried out to help identify the form of the enzyme that is present. Patients with known butyrylcholinesterase deficiency may wear a medic-alert bracelet that will notify healthcare workers of increased risk from administration of succinylcholine, and use a non-depolarising neuromuscular-blocking drug for general anesthesia, such as rocuronium. Prognosis for recovery following administration of succinylcholine is excellent when medical support includes close monitoring and respiratory support measures. In nonmedical settings in which subjects with butyrylcholinesterase deficiency are exposed to cocaine, sudden cardiac death can occur.
=== They Hunger === In the first episode, the player takes the role of a troubled writer who has gone to a country retreat to work on his next masterpiece. However, the player soon hears the news over the radio of 'strange atmospheric phenomena', and his car crashes into a lake after being struck by a lightning bolt. Severely wounded and armed only with a recharging flashlight, the player moves out to find help. His only means of escaping the lake is by swimming through a drainage pipe into a maze of catacombs. He comes to a mortuary chapel and finds an umbrella and medkits to heal himself with. Along the way, he's had several disturbing experiences: an unfinished catacomb is empty and has a splash of blood near it. The pathways are echoing screams of the damned. A bloodied skull rolls out of an ossuary, and as he enters the chapel, he hears someone screaming "No! No! Get it off me!", from who he takes his umbrella. As soon as he starts to leave, strange things start happening. A zombie breaks through a coffin and starts chasing him. The player has to smash the zombie down with the handle of the umbrella he took. He climbs the ladder to the church bell, only to find hostile headcrab-like creatures and a dead body. He takes a silenced 9mm Beretta pistol and rings the church bell for help. A vent opens and he climbs in to find some dynamite.
Sources: en.wikipedia.org
Legal status varies by country, but cardarine is not approved as a medicine in major jurisdictions. It is often sold as a research chemical, a category that may not be lawful for human use. Buyers should check local laws and product labels carefully.
Anti-doping laboratories use LC-MS/MS to detect GW501516 and its metabolites, usually in urine. The method can identify the parent compound at low concentrations. Detection windows vary with dose and individual factors.
No, cardarine has no approved medical uses in major jurisdictions. Early research explored metabolic conditions, but those programs were discontinued. It is not a registered treatment for any disease.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist. It is not a steroid or a selective androgen receptor modulator. It was developed and studied as a research compound for metabolic pathways.